PCO371 (PCO-371; PCO 371) is a novel, potent, selective and orally bioactive PTHR1 (parathyroid
hormone receptor 1) full agonist potentially for the treatment of
hypoparathyroidism. Orally administrating PCO371 to osteopenic rats
provokes a significant increase in bone turnover with limited increase
in bone mass. In hypocalcemic rats, PCO371 restores serum calcium levels
without increasing urinary calcium, and with stronger and
longer-lasting effects than PTH injections.